

Brucella anthropi bacteremia in an immunocompromised patient due to severe burn infection

Cynthia Bazán-Acevedo¹, Édgar Vanegas-Rodríguez², María Guadalupe Martínez-Zavaleta³, Luis Esau López-Jácome⁴, Andrea Méndez-Casillas⁵

Abstract

We present a clinical case of *Brucella anthropi* bacteremia associated with a central line catheter in an immunocompetent patient with a long hospital stay owing to complications from a burn injury. This is a man in his 20s who was admitted several days after being burned with oil (chicken fat) on the chest, upper limbs, genital area, and thighs, affecting 12% of the total body surface. The patient underwent various surgical procedures and subsequent skin grafting. The patient's progress was good after infection associated with the central venous catheter was treated, and the lesions were covered.

Keywords: Bacteremia; Burns; Central Venous Catheter

Bacteriemia por *Brucella anthropi* en un paciente inmunocomprometido debido a una infección severa asociada a quemadura

Resumen

Presentamos un caso clínico de bacteriemia por *Brucella anthropi* asociada a catéter venoso central en un paciente inmunocompetente con ingreso prolongado por complicaciones asociadas a una lesión por quemadura. Se trata de un varón en sus veintes, que ingresó varios días después de sufrir una quemadura por aceite (aceite de pollo), que afectó fundamentalmente tórax, miembros superiores, zona genital y muslos, comprometiendo el 12% de superficie corporal total, por lo que fue sometido a varios procedimientos quirúrgicos y a injertos cutáneos. El paciente evolucionó favorablemente tras el tratamiento de la infección asociada al catéter venoso central y la cobertura de sus lesiones.

Palabras clave: Bacteriemia; Quemaduras; Catéter venoso central

Introduction

The genus *Brucella* belongs to the class alpha-proteobacterial, this genus is integrated by 29 validated species. Recently, a new member was recategorized in this genus and came from another known as *Ochrobactrum*. *Ochrobactrum anthropi*, now *Brucella anthropi* is a gram-negative, rod-like, non-fermenting bacterium found in a wide variety of environments such as water, soil, plants, and animals. They are considered low-virulence pathogens and have recently been associated with opportunistic infection¹. As they can be found not only in natural environments, but also in water sources, including normal saline, antiseptic solutions, and dialysis, with a robust survival ability, they are mainly associated with hospital-

acquired infections, affecting mainly immunocompromised hosts with medical invasive devices^{2,3}. Management is complicated by its reported resistance profile to the most commonly used beta-lactams, such as cephalosporins and penicillin⁴.

Case report

A 28-year-old patient presented to the emergency department of a burn center with a scald burn injury. At the time of admission, the patient had a 20% burned body surface area, affecting both wrists and hands with third-degree burns, both thighs, and legs with second-degree burns, similar to the penis and scrotum. The patient underwent seven surgical wound toilets and debridement.

1 Unidad de Epidemiología Hospitalaria e Infectología. Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, México. <https://orcid.org/0009-0006-2800-0362>

2 División de Infectología. Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, México. <https://orcid.org/0000-0001-8328-3373>

3 Laboratorio de Microbiología Clínica, División de Infectología. Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, México. <https://orcid.org/0009-0008-5845-6146>

4 Laboratorio de Microbiología Clínica, División de Infectología. Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, México. <https://orcid.org/0000-0001-7387-0937>

5 Servicio de Agudos, División de Terapia Intensiva y Medicina Crítica. Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Ciudad de México, México. <https://orcid.org/0009-0004-5028-2445>

* Autor para correspondencia:
Correo electrónico: vanrodgrr@gmail.com

Recibido: 22/08/2024; Aceptado: 23/01/2025

Cómo citar este artículo: C. Bazán-Acevedo, et al. *Brucella anthropi* bacteremia in an immunocompromised patient due to severe burn infection. *Infectio* 2025; 29(2): 125-127

On the 29th day after the burn injury, he was transferred to our center. Upon admission, the patient had a 12% burned body surface area without clinical signs of infection and a subclavian right central line. In the first hours of hospitalization, the patient presented 2 hours fever, central and peripheral blood cultures and urine cultures were taken, and the central line and urinary catheter were removed.

On the day after admission, the patient underwent tangential excision and grafting in the burned areas. On the first day after taking, blood cultures from central line were reported positive, with Gram stain showing gram-negative bacilli (figure 1-a). After 48 hours of inoculation, a Gram negative, non-lactose fermenter bacillus was reported in both blood cultures taken from central line and catheter tip culture (figure 1-b) and empirical meropenem was administered.

Brucella anthropi was identified in the central line and catheter tip cultures using Vitek MS. The reported susceptibilities of the bacteria were cephalosporin, carbapenem, and colistin resistance, and the rest of the antibiogram was susceptible; therefore, meropenem was suspended, and the patient was treated with levofloxacin.

Six days after removal of the central line, the patient had no new events of fever, no clinical signs of bacteremia, no other clinical signs of infection, serum inflammatory markers normalized, and wounds showed no signs of infection. Therefore, the patient continued medical treatment at home for two weeks.




Figure 1. a) blood central line cultures in gram stain light microscopic examination showing clusters of gram-negative bacilli. b) *Brucella anthropi* in blood agar after 48 hours of incubation.

Discussion

Immune dysfunction is a hallmark of critical illness. Severe burn injuries are associated with proinflammatory and anti-inflammatory responses, leading to immunosuppression⁵. In severe burn injuries, there is a prolonged and strong immune response, leading to multiple systemic effects such as multiple organ failure due to systemic inflammatory response syndrome (SIRS)⁶. Immunosuppression and prolonged inflammatory response lead to infectious complications⁷.

Pathogens affecting burn patients change over time; the first days of hospitalization are those of the skin flora and occasionally those of the digestive system. During prolonged hospitalization, these pathogens are replaced by colonization by hospital bacteria, mainly gram-negative bacilli, such as *Pseudomonas aeruginosa* and other *Enterobacteriales*⁸. One of the main infections in burn patients is bloodstream infections. Most patients with severe burn injuries have invasive devices such as central bloodline catheters, which are the optimal port of entrance to the bloodstream⁹. Moreover, severe burn injuries are associated with prolonged hospital stay, and most patients undergo multiple surgical procedures, which increase the risk of bloodstream infections¹⁰.

Pathogens associated with these infections are mainly Gram-negative rods, like *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Acinetobacter baumannii* and yeast like *Candida spp.*¹¹. With the worldwide increase in antibiotic resistance, burn patients are at high risk of acquiring infections by multidrug-resistant (MDR) organisms¹².

Brucella anthropi has been recognized as an opportunistic emerging infection associated with a long hospital stay, invasive medical devices, and immunocompromised hosts. The *Brucella* genus consists of non-fermentative, strictly aerobic, oxidase-positive, and indole rapid-negative gram-negative rods¹³.

Brucella anthropi has been reported as an etiological agent associated with infection. In their literature review, Ryan et al. *Brucella anthropi* was associated with 46 bloodstream infections that were usually associated with catheters, 14 septicemia, two biliary sepsis, nine endophthalmitis, eight peritonitis, four pneumonia and two endocarditis¹⁴.

Treatment with *Brucella anthropi* represents a therapeutic challenge because of its increased association with resistance, and most isolates have been reported to be resistant to β -lactams due to a chromosomal, induced AmpC β -lactamase, which is resistant to clavulanic acid inhibition. It is generally considered to be susceptible to quinolones, trimethoprim/sulfamethoxazole, and colistin¹⁵.

In this clinical case, we present a bloodstream-related infection caused by *Brucella anthropi* in a previously healthy patient with a severe burn injury. The main associated risk factors were prolonged hospital stay, use of intravenous devices, multiple surgical events within the course of hospitalization, and use of broad-spectrum antibiotics. Microbiologic identification was performed using biochemical tests and confirmed with Vitek

MS; however, reports of antibiotic susceptibilities were challenging because initial resistance to quinolones was discordant between isolations. Therefore, manual susceptibility tests were performed to confirm the susceptibility patterns. Genus *Brucella* are facultative intracellular parasites. Recently, *Brucellae* merged with *Ochrobactrum* spp. in the genus *Brucella*, based only on global genomic analysis. Some microbiologists believe this is incorrect because it was performed without a thorough phylogenetic analysis and poses a risk to those working with brucellosis. They suggested that the terms *Ochrobactrum* and *Brucella* remain valid separately¹⁶.

In conclusion, *Brucella anthropi* is a gram-negative bacillus recently associated with opportunistic infections in immunocompromised hosts. Infections related to these bacteria are primarily bloodstream infections. Patients with severe burn injuries are at an increased risk of developing complicated infections due to immune dysfunction.

The diagnosis and treatment of *Brucella anthropi* infections are challenging because of low clinical suspicion, different methods of identification, and resistance patterns. In this clinical case, the patient had multiple risk factors that increased the risk of acquiring opportunistic infections, and identification was performed in the microbiology laboratory.

To our knowledge, this is the first report of a *Brucella anthropi* bloodstream infection in a patient with severe burns. We conclude that knowledge of the prevalence of infections associated with this microbiological agent, methods of identification, and resistance patterns must be increased to raise awareness of the capability of infection and complications of this agent and to provide better and more effective treatment strategies in high-risk populations.

Ethical considerations

Protection of persons. No experiments were performed on humans or animals.

Protection of vulnerable populations. The patient described in this clinical case is not part of a vulnerable population.

Confidentiality. We have considered the confidentiality of personal data have been respected.

Privacy. We have considered the privacy of personal data have been respected.

Financing. We have not received any type of funding for the realization of this work.

Conflict of interests. The authors have no conflict of interest to declare.

Acknowledgments. To our knowledge, this is the first case of bacteremia associated with this bacteria, whose nomenclature has recently changed, in a severely burned patient. A germ that also represents a challenge for its identification and typing in the clinical microbiology laboratory.

Authors' contribution. CB, EV, AM: clinical care of the case; conception and design of the manuscript as well as documentation of the case. EL, MM: microbiological diagnostic procedures, bacterial identification and revision of the document. All authors contributed to read and approved the version of the submitted manuscript.

References

1. Parte, A. C., Sardà Carbasse, J., Meier-Kolthoff, J. P., Reimer, L. C., & Göker, M. (2020). List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. *International Journal of Systematic and Evolutionary Microbiology*, 70(11), 5607–5612. <https://doi.org/10.1099/ijsem.0.004332>
2. Anjana, A., Adhikary, R., Bhavana, M. V., & Beena, H. B. (2022). Two Case Reports of *Ochrobactrum anthropi* Bacteremia: An Overlooked Pathogen. *Journal of Laboratory Physicians*, 15(1), 166–168. <https://doi.org/10.1055/s-0042-1757235>
3. Mudshingkar, S., Choure, A., Palewar, M., Dohe, V., & Kagal, A. (2013). *Ochrobactrum anthropi*: An unusual pathogen: Are we missing them? *Indian Journal of Medical Microbiology*, 31(3), 306–308. <https://doi.org/10.4103/0255-0857.115664>
4. *Ochrobactrum anthropi* – An Emerging Opportunistic Pathogen in Musculoskeletal Disorders – A Case Report and Review of Literature | *Journal of Orthopaedic Case Reports*. (n.d.). <https://doi.org/10.13107/jocr.2022.v12.i03.2730>
5. Moins-Teisserenc, H., Cordeiro, D. J., Audigier, V., Ressaire, Q., Benyamina, M., Lambert, J., Maki, G., Homyrda, L., Toubert, A., & Legrand, M. (2021). Severe Altered Immune Status After Burn Injury Is Associated With Bacterial Infection and Septic Shock. *Frontiers in Immunology*, 12. <https://doi.org/10.3389/fimmu.2021.586195>
6. Burgess, M., Valdera, F., Varon, D., Kankuri, E., & Nuutila, K. (2022). The Immune and Regenerative Response to Burn Injury. *Cells*, 11(19), Article 19. <https://doi.org/10.3390/cells11193073>
7. Kelly, E. J., Oliver, M. A., Carney, B. C., & Shupp, J. W. (2022). Infection and Burn Injury. *European Burn Journal*, 3(1), Article 1. <https://doi.org/10.3390/ejb3010014>
8. Hidalgo, F., Mas, D., Rubio, M., & Garcia-Hierro, P. (2016). Infections in critically ill burn patients. *Medicina Intensiva (English Edition)*, 40(3), 179–185. <https://doi.org/10.1016/j.medine.2016.02.002>
9. Nitsani, Y., Michael, T., Halpern, D., Hasidim, A. A., Sher, M., Givoli Vilensky, R., Krieger, Y., Silberstein, E., & Shoham, Y. (2023). Blood Stream Infections in Burns: A 14-Year Cohort Analysis. *Life*, 13(6), Article 6. <https://doi.org/10.3390/life13061357>
10. Hu, Y., Li, D., Xu, L., Hu, Y., Sang, Y., Zhang, G., & Dai, H. (2021). Epidemiology and outcomes of bloodstream infections in severe burn patients: A six-year retrospective study. *Antimicrobial Resistance & Infection Control*, 10(1), 98. <https://doi.org/10.1186/s13756-021-00969-w>
11. Zampar, E. F., Anami, E. H. T., Kerbaudy, G., Queiroz, L. F. T., Carrilho, C. M. D. M., Cardoso, L. T. Q., & Grion, C. M. C. (2017). Infectious complications in adult burn patients and antimicrobial resistance pattern of microorganisms isolated. *Annals of Burns and Fire Disasters*, 30(4), 281–285.
12. Rueggsegger, L., Xiao, J., Naziripour, A., Kanumuambidi, T., Brown, D., Williams, F., Marshall, S. H., Rudin, S. D., Yen, K., Chu, T., Chen, L., Sozzi, E., Bartelt, L., Kreiswirth, B., Bonomo, R. A., & van Duin, D. (2022). Multidrug-Resistant Gram-Negative Bacteria in Burn Patients. *Antimicrobial Agents and Chemotherapy*, 66(9), e00688-22. <https://doi.org/10.1128/aac.00688-22>
13. Teyssier, C., Marchandin, H., Jean-Pierre, H., Diego, I., Darbas, H., Jeannot, J.-L., Gouby, A., & Jumas-Bilak, E. (2005). Molecular and phenotypic features for identification of the opportunistic pathogens *Ochrobactrum* spp. *Journal of Medical Microbiology*, 54(10), 945–953. <https://doi.org/10.1099/jmm.0.46116-0>
14. Ryan, M. P., & Pembroke, J. T. (2020). The Genus *Ochrobactrum* as Major Opportunistic Pathogens. *Microorganisms*, 8(11), Article 11. <https://doi.org/10.3390/microorganisms8111797>
15. Hagiya, H., Ohnishi, K., Maki, M., Watanabe, N., & Murase, T. (2020). Clinical Characteristics of *Ochrobactrum anthropi* Bacteremia. *Journal of Clinical Microbiology*, 57(4), 1330–1333. <https://doi.org/10.1128/jcm.03238-12>
16. Moreno E, Middlebrook EA, Altamirano-Silva P, Al Dahouk S, Araj GF, Arce-Gorvel et al. (2023) .If You're Not Confused, You're Not Paying Attention: *Ochrobactrum* Is Not *Brucella*. *J Clin Microbiol*61: e00438-23.